Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2384-2389

  Qiu, Li Xin ^a   Tang, Qi Yun ^a   Bai, Jian Ling ^a   Qian, Xiao Ping ^a,b   Li, Ru Tian ^b   Liu, Bao Rui ^a,b   Zheng, Ming Hua ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Advanced colorectal cancer; Fluoropyrimidine based chemotherapy; Metaanalysis; Predictive value; Thymidylate synthase

Indexed keywords

CAPECITABINE; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; TEGAFUR; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; META ANALYSIS; METASTASIS; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; TUMOR; COLORECTAL TUMOR; ENZYMOLOGY; METABOLISM; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYMIDYLATE SYNTHASE;

EID: 53449098390     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23822     Document Type: Article

References (35)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
2. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
3. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977;473:73-92.
4. Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000;11:385-91.
5. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-12.
6. Berger SH, Jenh CH, Johnson LF, Berger FG. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985;28:461-7.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
8. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
9. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 1997;75:903-9.
10. Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
11. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-9.
12. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998;4:1243-50.
13. Davies MM, Johnston PG, Kaur S, Allen-Mersh TG. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 1999;5:325-8.
14. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J. Thymidilate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-7.
15. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000;6:4797-802.
16. Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 2000;89:288-96.
17. Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 2000;11:1053-6.
18. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
19. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002;20:2832-43.
20. Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002;13:1882-92.
21. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
22. Johnston PG, Benson AB 3rd, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J. Clin Oncol 2003;21:815-9.
23. Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol 2004;15:55-8.
24. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;111:252-8.
25. Hosokawa A, Yamada Y, Shimada Y, Muro K, Hamaguchi T, Morita H. Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. Int J Clin Oncol 2004;9:388-92.
26. Xu JM, Zhu BD, Mangia A, Simone G, Montemurro S, Giuliani F, Maiello E, Colucci G, Paradiso A. Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment. Zhonghua Zhong Liu Za Zhi 2005;27:312-5 (Chinese).
27. Ishida H, Shirakawa K, Ohsawa T, Sobajima J, Hayashi Y, Nakada H. Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer-relationships among mRNA levels in association with response to 5-FU based treatment. Gan To Kagaku Ryoho 2005;32:1929-34.
28. Bendardaf R, Lamlum H, Elzagheid A, Ristamaki R, Pyrhonen S. Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. Oncol Rep 2005;14:657-62.
29. Lindebjerg J, Nielsen JN, Hoeffding LD, Jakobsen A. Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica 2005;113:600-2.
30. Yanagisawa Y, Maruta F, Iinuma N, Ishizone S, Koide N, Nakayama J. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. Scand J Gastroenterol 2007;42:477-84.
31. Iyevleva AG, Buslov KG, Togo AV, Matsko DE, Filimonenko VP, Moiseyenko VM. Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees. Onkologie 2007;30:295-300.
32. Nakajima TE, Yamada Y, Shimoda T, Matsubara J, Kato K, Hamaguchi T. Combination of O(6)-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy. Eur J Cancer 2008;44:400-7.
33. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-36.
34. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003.
35. Marsh S, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep 2002;9:231-4.